"When deployed without supporting lifestyle interventions, clinical oversight, and coordination across benefits, GLP-1s risk delivering short-term results without long-term health improvement. ... Employers should view these medications as one component of a broader obesity and metabolic health strategy ... This approach recognizes both the clinical promise of GLP-1s and the practical realities of cost, sustainability, and long-term population health."  MORE >>